ALE-C04
- Generic Name
- ALE-C04
Study of ALE.C04 in Patients With Head and Neck Cancer
Phase 1
Terminated
- Conditions
- Head and Neck CancerHead and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2023-09-26
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- Alentis Therapeutics AG
- Target Recruit Count
- 21
- Registration Number
- NCT06054477
- Locations
- 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸University of Southern California USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Yale University Yale Cancer Center, New Haven, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath